In addition, both IL-1β and IL-6 are also known as key mediators in chronic inflammation and are associated with long-term hemodialysis complications such as erythropoietin hyporesponsiveness, cardiovascular morbidities and amyloidosis-related bone disease (27,28). Here, IL1B is linked to amyloidosis.